VEGF-A Controls the Expression of Its Regulator of Angiogenic Functions, Dopamine D2 Receptor, on Endothelial Cells

Overview

Journal J Cell Sci

Specialty Cell Biology

Date 2022 May 20

PMID 35593650

Authors

Chandrani Sarkar

Debanjan Chakroborty

Sandeep Goswami

Hao Fan

Xiaokui Mo

Sujit Basu

Affiliations

Soon will be listed here.

Abstract

We have previously demonstrated significant upregulation of dopamine D2 (DAD2) receptor (DRD2) expression on tumor endothelial cells. The dopamine D2 receptors, upon activation, inhibit the proangiogenic actions of vascular endothelial growth factor-A (VEGF-A, also known as vascular permeability factor). Interestingly, unlike tumor endothelial cells, normal endothelial cells exhibit very low to no expression of dopamine D2 receptors. Here, for the first time, we demonstrate that through paracrine signaling, VEGF-A can control the expression of dopamine D2 receptors on endothelial cells via Krüppel-like factor 11 (KLF11)-extracellular signal-regulated kinase (ERK) 1/2 pathway. These results thus reveal a novel bidirectional communication between VEGF-A and DAD2 receptors.

Citing Articles

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

Chen Y, Dai S, Cheng C, Chen L J Hematol Oncol. 2024; 17(1):130.

PMID: 39709431 PMC: 11663365. DOI: 10.1186/s13045-024-01647-1.

Effect of Dopamine as a Vascular Endothelial Growth Factor Antagonist on the Development of Acute Lung Injury in Sepsis Patients.

Agarwal S, Srivastava V, Arshad Z, Sharma P, Prakash R Cureus. 2024; 16(7):e64102.

PMID: 39114208 PMC: 11305694. DOI: 10.7759/cureus.64102.

The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.

Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675421 PMC: 11053547. DOI: 10.3390/ph17040461.

Therapeutic Immunomodulation in Gastric Cancer.

Akkanapally V, Bai X, Basu S Cancers (Basel). 2024; 16(3).

PMID: 38339311 PMC: 10854796. DOI: 10.3390/cancers16030560.

Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis.

Mendoza-Torreblanca J, Cardenas-Rodriguez N, Carro-Rodriguez J, Contreras-Garcia I, Garciadiego-Cazares D, Ortega-Cuellar D Int J Mol Sci. 2023; 24(12).

PMID: 37373348 PMC: 10299003. DOI: 10.3390/ijms241210199.

References

Bryant K, Stalnecker C, Zeitouni D, Klomp J, Peng S, Tikunov A . Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019; 25(4):628-640. PMC: 6484853. DOI: 10.1038/s41591-019-0368-8. View

Zhang Y, Hoda M, Zheng X, Li W, Luo P, Maddipati K . Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition. Am J Physiol Regul Integr Comp Physiol. 2014; 307(6):R693-703. PMC: 4214836. DOI: 10.1152/ajpregu.00422.2013. View

Seo S, Lomberk G, Mathison A, Buttar N, Podratz J, Calvo E . Krüppel-like factor 11 differentially couples to histone acetyltransferase and histone methyltransferase chromatin remodeling pathways to transcriptionally regulate dopamine D2 receptor in neuronal cells. J Biol Chem. 2012; 287(16):12723-35. PMC: 3339994. DOI: 10.1074/jbc.M112.351395. View

Yang H, Yang J, Cheng H, Cao H, Tang S, Wang Q . Probiotics ingestion prevents HDAC11-induced DEC205+ dendritic cell dysfunction in night shift nurses. Sci Rep. 2019; 9(1):18002. PMC: 6884592. DOI: 10.1038/s41598-019-54558-4. View

Simons M, Gordon E, Claesson-Welsh L . Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016; 17(10):611-25. DOI: 10.1038/nrm.2016.87. View

Tejada M, Santos-Llamas A, Fernandez-Ramirez M, Tarin J, Cano A, Gomez R . A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment. Biomedicines. 2021; 9(3). PMC: 8001569. DOI: 10.3390/biomedicines9030269. View

Garcia J, Hurwitz H, Sandler A, Miles D, Coleman R, Deurloo R . Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020; 86:102017. DOI: 10.1016/j.ctrv.2020.102017. View

Nagy J, Dvorak A, Dvorak H . VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med. 2003; 13(5):169-75. DOI: 10.1016/s1050-1738(03)00056-2. View

Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra R, Dasgupta P . Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 2004; 64(16):5551-5. DOI: 10.1158/0008-5472.CAN-04-1600. View

10.

Basu S, Nagy J, Pal S, Vasile E, Eckelhoefer I, Bliss V . The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001; 7(5):569-74. DOI: 10.1038/87895. View

11.

Chakroborty D, Sarkar C, Mitra R, Banerjee S, Dasgupta P, Basu S . Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res. 2004; 10(13):4349-56. DOI: 10.1158/1078-0432.CCR-04-0059. View

12.

Dou L, Sallee M, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N . The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol. 2014; 26(4):876-87. PMC: 4378098. DOI: 10.1681/ASN.2013121283. View

13.

Dvorak H . Angiogenesis: update 2005. J Thromb Haemost. 2005; 3(8):1835-42. DOI: 10.1111/j.1538-7836.2005.01361.x. View

14.

Chauvet N, Romano N, Lafont C, Guillou A, Galibert E, Bonnefont X . Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model. Int J Cancer. 2017; 140(9):2150-2161. DOI: 10.1002/ijc.30628. View

15.

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

16.

Zheng Y, Khan Z, Zanfagnin V, Correa L, Delaney A, Daftary G . Epigenetic Modulation of Collagen 1A1: Therapeutic Implications in Fibrosis and Endometriosis. Biol Reprod. 2016; 94(4):87. DOI: 10.1095/biolreprod.115.138115. View

17.

Beaulieu J, Espinoza S, Gainetdinov R . Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015; 172(1):1-23. PMC: 4280963. DOI: 10.1111/bph.12906. View

18.

Richards E, Zheng Y, Shenoy C, Ainsworth A, Delaney A, Jones T . KLF11 is an Epigenetic Mediator of DRD2/Dopaminergic Signaling in Endometriosis. Reprod Sci. 2017; 24(8):1129-1138. DOI: 10.1177/1933719117698582. View

19.

Chakroborty D, Sarkar C, Lu K, Bhat M, Dasgupta P, Basu S . Activation of Dopamine D1 Receptors in Dermal Fibroblasts Restores Vascular Endothelial Growth Factor-A Production by These Cells and Subsequent Angiogenesis in Diabetic Cutaneous Wound Tissues. Am J Pathol. 2016; 186(9):2262-70. PMC: 5012463. DOI: 10.1016/j.ajpath.2016.05.008. View

20.

Turner J, Crossley M . Mammalian Krüppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci. 1999; 24(6):236-40. DOI: 10.1016/s0968-0004(99)01406-1. View